Related coverage linked through entity extraction aliases.
Jun 12, 2026
A French cohort study found nirsevimab at birth reduces RSV-related hospitalizations in infants by 22% compared to maternal vaccination. UK data shows the maternal RSV vaccine provides over 80% protection when given at least four weeks before birth. Both strategies aim to protect vulnerable infants during their first months of life.
May 07, 2026
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
Apr 17, 2026
The European Commission approved Enflonsia for prevention of RSV lower respiratory tract disease in infants during their first RSV season. Merck also reported new Phase 3 SMART data showing generally consistent second-season safety in high-risk children under 2 years old.
